RecruitingAlzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Eligible age
55–80 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Body weight of 150 kg or less
- ✓ Willingness and ability to complete all aspects of the study for the duration of the study
- ✓ Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
- ✓ Cognitively and functionally unimpaired as defined by the protocol
- ✓ Availability of a study partner as defined by the protocol
- ✓ A plasma pTau217 level consistent with a high likelihood of future clinical progression
You may not qualify if…
- ✕ Any evidence of a condition other than AD that may affect cognition, including, but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson disease, corticobasal syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration (other than frontotemporal dementia), Huntington disease, normal pressure hydrocephalus, seizure disorder, delirium, or hypoxia
- ✕ Mild cognitive impairment (MCI; may be referred to as prodromal AD), or any form of dementia
- ✕ History or presence of clinically significant cerebrovascular disease
- ✕ History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma
- ✕ History or presence of clinically significant intracranial mass
- ✕ History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
- ✕ History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 12 months of an acute event that is consistent, in the opinion of the PI, with a transient ischemic attack
- ✕ At risk for suicide in the opinion of the investigator
Where it's recruiting
Source: ClinicalTrials.gov · NCT07717411 · last updated 2026-09-10